<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224702</url>
  </required_header>
  <id_info>
    <org_study_id>MS200572-0009</org_study_id>
    <secondary_id>2017-001663-21</secondary_id>
    <nct_id>NCT03224702</nct_id>
  </id_info>
  <brief_title>First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers</brief_title>
  <official_title>A Single-Center, Phase I, Randomized, Double Blind, Placebo-Controlled, First-In-Human Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Subcutaneous Injected M6495 (Anti-ADAMTS-5 Nanobody) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This First-In-Human trial will be conducted in healthy male subjects to explore the safety,
      tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of single doses of
      M6495.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Anticipated">August 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)</measure>
    <time_frame>Baseline up to Day 75</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of TEAEs and SAEs by Severity</measure>
    <time_frame>Baseline up to Day 75</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Injection Site Reactions (ISRs)</measure>
    <time_frame>Baseline up to Day 75</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to Day 75</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax) of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero to the Last Sampling Time (t) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life (t1/2) of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (Î»z) of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Body Clearance (CL/F) of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase (Vz/F) of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Aggrecan Degradation neo-Epitope (ARGS) at Day 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 22, 29, 39, 49, 61 and 75</measure>
    <time_frame>Baseline, Day 1, 2, 3, 4, 5, 6, 7, 8, 11, 15, 22, 29, 39, 49, 61 and 75</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-drug Antibodies (ADA) for M6495</measure>
    <time_frame>Pre-dose, Day 8, 22, 49 and 75</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Anti-Drug Antibodies (ADA) Titers</measure>
    <time_frame>Pre-dose, Day 8, 22, 49 and 75</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Telemetry Electrocardiogram (ECG) Intervals Up to 24 hours post Day 1 dose</measure>
    <time_frame>Baseline, Up to 24 hours post Day 1 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of Exposure vs QTc From Digital Electrocardiogram Triplicates</measure>
    <time_frame>Baseline up to Day 75</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Effect (Imax) of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibitory Concentration (IC) 10, IC50 and IC90 of M6495</measure>
    <time_frame>Pre-dose and 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 912, 1152, 1440, 1776 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>M6495</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M6495</intervention_name>
    <description>Subjects will receive M6495 on Day 1</description>
    <arm_group_label>M6495</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo matched to M6495 on Day 1</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Body Mass Index (BMI) of greater than or equal to (&gt;=) 18.5 and less
             than or equal to (=&lt;) 29.9 Kilogram per square meter (kg/m^2), and a body weight
             between 50 and 100 kg at screening.

          -  Subjects must agree to use effective method(s) of contraception during the trial.

          -  Other protocol defined inclusion criteria could apply.

        Exclusion Criteria:

          -  Subjects who have recently participated in other clinical trials.

          -  Donated blood, have a significant medical condition, history of drug hypersensitivity,
             consumption of large amounts of xanthine-containing foods or beverages, recent or
             ongoing concomitant medication, hypertension, tachycardia and significant findings on
             electrocardiogram

          -  Positive drug screening test, positive test for Hepatitis B or C or human immune
             deficiency virus (HIV), or have been kept in detention

          -  Other protocol defined exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>DanTrials ApS c/o Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
    <investigator>
      <last_name>Jesper Sonne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M6495</keyword>
  <keyword>anti-A disintegrin and metalloproteinase with thrombospondin motifs-5 nanobody</keyword>
  <keyword>Osteoarthritis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

